FDA sanctions don't kill a business

Share this article:

FDA sanctions may not be the end for a drugmaker. Bloomberg reports that India's Wockhardt Ltd., which was hit with enough violations that the FDA banned products from two of its plants, expects sales to hit $1 billion in 2017, thanks to domestic (as in non-US) sales.

Bloomberg says the firm has become a possible M&A target for peer and neighbor Lupin, Ltd.

“What's attractive about this company, in spite of the import alerts, is its presence in India, the US and Europe,” CIMB securities analyst Prakash Agarwal tells Bloomberg.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters